Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director
Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/15/2023 8-K Investor presentation, Quarterly results
Docs: "End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris",
"Corporate Presentation"
01/25/2023 8-K Investor presentation
Docs: "Investor Presentation Materials",
"[email protected]"
08/12/2022 8-K Investor presentation, Quarterly results
Docs: "Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy",
"Corporate Presentation"
05/19/2022 8-K Quarterly results
03/29/2022 8-K Investor presentation
Docs: "Investor Presentation Materials",
"Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol ® in the Reversal of Mydriasis"
01/05/2022 8-K Investor presentation
Docs: "Initiated Enrollment in MIRA-4 Pediatric Trial in Reversal of Mydriasis: Ocuphire recently enrolled the first subjects in MIRA-4, which is a randomized, double-masked, placebo-controlled study of Nyxol eye drops to reverse pharmacologically-induced mydriasis in healthy pediatric subjects. Approximately 20 pediatric subjects ages 3 to 11 will be enrolled with safety as the primary objective and efficacy as secondary objectives. Nyxol has the potential to address an estimated $500 million reversal of dilation market across pediatrics and adults, which has no current commercially available therapies. Completed Enrollment of LYNX-1study in Night Vision Disturbances: Enrollment has been completed in the LYNX-1 Phase 3 clinical trial investigating Nyxol for the treatment of NVD. LYNX-1 is a rand...",
"Corporate Presentation"
08/12/2021 8-K Investor presentation, Quarterly results
Docs: "Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update",
"Corporate Presentation"
06/30/2021 8-K Quarterly results
01/06/2021 8-K Investor presentation
Docs: "Corporate Presentation, dated January 2021"
11/06/2020 8-K Investor presentation, Director compensation was amended/approved, Acquisition/merger/asset purchase announced
Docs: "Certificate of Amendment (Reverse Stock Split) to the Certificate of Incorporation of the Company",
"Certificate of Amendment (Name Change) to the Certificate of Incorporation of the Company",
"Second Amended and Restated Bylaws of the Company",
"Contingent Value Rights Agreement, by and among the Company, Shareholder Representative Services LLC and the Olde Monmouth Stock Transfer Co., Inc",
"INDEMNITY AGREEMENT",
"1. Annual Board Service Retainer: All Eligible Directors: $40,000 Chair of the Board : $35,000 Lead Independent Director : $20,000 2. Annual Committee Member Service Retainer: Member of the Audit Committee: $7,500 Member of the Compensation Committee: $5,000 Member of the Nominating and Corporate Governance Committee: $4,000 1",
"Code of Business Conduct and Ethics of the Company",
"Letter from Baker Tilly",
"About Ocuphire Pharma",
"Ocuphire Corporate Presentation"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy